• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

160.31 +2.31 (+1.46%)
Delayed Quote Updated: 3:49 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,702,912
Open 158.94
Bid (Size) 160.27 (240)
Ask (Size) 160.35 (280)
Prev. Close 158.00
Today's Range 156.72 - 161.58
52wk Range 156.00 - 479.79
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
Today 8:30 EST
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Top US Stock Gainers and Losers for Oct. 29, 2026 ↗
October 29, 2026
Via Chartmill

Performance

52-Week Range 66.6% below 52-week high
160.31
156.0052W Low 479.7952W High
1 Week 31.2% below 1-week high
156.001W Low 232.881W High

Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY) traded between $156.00 and $479.79 over the past 52 weeks and last traded at $160.31, 66.6% below its 52-week high. Over the past week it ranged between $156.00 and $232.88.

Past 12 Months
-29.3%
-27.1%
-27.2%
-46.2%
-59.9%
-63.1%
1W -$66.48
1M -$59.58
3M -$60.02
6M -$137.62
YTD -$239.86
1Y -$273.76

ALNY was -63.1% over the past year, -46.2% over six months, -59.9% year to date, -29.3% in the last week.

12 Months vs Market
ALNY
-63.1%
DIA
+9.1%
SPY
+10.4%
QQQ
+8.6%
IWM
+14.1%

Over the past 12 months ALNY returned -63.1% versus DIA (Dow) +9.1%, SPY (S&P 500) +10.4%, QQQ (Nasdaq 100) +8.6% and IWM (Russell 2000) +14.1%.

Volume & Liquidity 1.44× 3-mo avg
Today 2,702,912 3-mo avg 1.9M
1W
5.4M
1M
2.3M
3M
1.9M
6M
1.7M
YTD
1.5M
1Y
1.5M

ALNY most recently traded 2,702,912 shares against a 3-month average daily volume of 1.9M.

More News

Read More
News headline image
Alnylam (ALNY) Q3 2026 Earnings Call Transcript ↗
October 29, 2026
Via The Motley Fool
Topics Earnings
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum ↗
October 16, 2026
Via Chartmill
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth ↗
October 08, 2026
Via Chartmill
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech ↗
September 03, 2026
Via Chartmill
News headline image
Alnylam Pharmaceuticals Q3 Earnings Call Highlights ↗
October 29, 2026
Via MarketBeat
Topics Earnings
Premarket Gainers and Losers on Oct. 29, 2026 ↗
October 29, 2026
Via Chartmill
News headline image
Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress
October 29, 2026
From Alnylam Pharmaceuticals
Via Business Wire
News headline image
Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial ↗
October 26, 2026
Via MarketBeat
News headline image
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease
October 23, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗
October 21, 2026
Via The Motley Fool
News headline image
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
October 15, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗
October 10, 2026
Via The Motley Fool
News headline image
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
September 29, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗
September 28, 2026
Via The Motley Fool
News headline image
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook ↗
September 20, 2026
Via MarketBeat
News headline image
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial ↗
September 19, 2026
Via MarketBeat
Topics Death
News headline image
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗
September 15, 2026
Via The Motley Fool
News headline image
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗
September 11, 2026
Via Benzinga
News headline image
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
September 02, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
August 30, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗
August 28, 2026
Via Benzinga
News headline image
Alnylam Pharmaceuticals, Inc. Investors: Investigation Launched Into Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by Kessler Topaz Meltzer & Check, LLP
August 24, 2026
Via NewMediaWire
News headline image
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
August 24, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 160.31
When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 11/03/26 03:49 PM ET
What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 19.05B
How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
Alnylam Pharmaceuticals, Inc. - Common Stock has 19B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap